atl1103 development update, page-29

It is great for Mark Diamond to provide us with an update on ATL1103.

Just cross checking with my post dated 2nd Jan on ATL1103

ATL1103

1. Dr.Cohen of UCLA pituitary tumor program should advise that based on Phase 1 trial results, whether ATL1103 will be worth pursuing for the Pituitary Tumor and if this will open up the a separate line of reserach for ATL1103.  

The cancer marker of Phase 1 result is still too subtle to commit. Will have to wait for Phase 2 results where a larger sample and longer dosing may provide better indicator.

2. Based on TEVA's previous licensing agreement for ATL1102 for MS, it would be anticipate that the Pharma who is in DD on ATL1103 could make an offer to continue the trials from Phase2 onwards. Ideally, this is for a different line of research such as for the Pituitary Cancer trials. Leaving the original Acromegaly line of research to ANP through private funding.

An experienced drug development pharma is now undertaking more comprehensive due diligence with an expanded package of additional data and IP relating to ATL1103.

There is some speculation that Pfizer may fit the bill as it has Somavert for Acromegaly. More so ANP has lodged a US patent on the 'Combined Theraphy' of Acromegaly using Somavert and ATL1103.

I hope that Pfizer or whoever the Pharma is, could make a very good offer to take ATL1103 to commercialisation.

In the years since Pfizer's commercial launch of SOMAVERT, Ohio University has received more than $75 million in royalty income from the license.

Other than upfront and milestone payments, It would be great if ANP can get a royalties deal similar to that either as stand alone therapy or combined therapy.

3. Annoucements on the details of ATL1103 Phase 2 human trials : funding arrangements, timeline etc.
Once the details of Phase 2 trials is finalised, we should expect a funding arrangements probably thru SI, a joint annoucement with ISIS in the US for the initiation of Phase 2a human trial, presentation to ISIS US investors, Phase 2a plan approval, recruitment drive and the 12 weeks trial for Phase 2a and a longer term Phase 2b.

The trial is expected to commence by or prior to mid 2012. This would mean the details and funding arrangements should be within the next 1-2 months, giving sufficent time for trial subject recruitment.

Could this be the timeframe the Pharma may make an offer before Phase 2 begins so as to get a better deal for them? We shall see.

Phase 2a is a 12 weeks trial. Phase 2b is a longer term 18 months trial, probably when a licensing partner is on board.




We should also expect the update for ATL1101 and ATL1102 soon.


JIMO  DYOR